Breaking AI & Tech News Analyzed

President Donald Trump has announced a new policy threatening to impose 100% tariffs on US pharmaceutical companies that do not agree to lower their drug prices. This move is part of his effort to address the high cost of prescription medications in the US.The tariffs will specifically target branded drugs and their active ingredients, while generic drugs, which account for over 90% of medicines sold in the US, will be exempt for at least one year. Additionally, certain specialty drugs, such as orphan, veterinary, and other specialty drugs, will be exempt if they are from countries with which the US has a trade deal or meet urgent public health needs.Drugmakers that enter into pricing agreements with the White House and onshore drug production will be exempt from the tariffs. Companies planning to increase their domestic manufacturing will face a 20% tariff that will escalate to 100% over four years.The policy has been met with criticism from industry groups, such as the Midsized Biotech Alliance of America (MBAA), which argues that it creates an "unfair two-tiered system" that benefits large companies with diversified portfolios.Trump has been under pressure to lower drug prices, with US patients often paying nearly triple what patients pay in other developed nations. The announcement comes as the White House faces pressure from consumers to address rising costs amid other tariff-related price increases and high gas prices triggered by geopolitical tensions.

The U.S. Food and Drug Administration announced on Wednesday that it has granted expedited approval to Eli Lilly’s oral weight‑loss medication, orforglipron—marketed under the brand name Foundayo. This makes Foundayo the second GLP‑1 pill to reach U.S. consumers, following Novo Nordisk’s Wegovy tablet approved in December. Orforglipron works by mimicking a natural hormone that regulates appetite and satiety, offering a non‑injectable alternative to existing GLP‑1 injectables. David A. Ricks, Eli Lilly’s chair and CEO, highlighted that fewer than one in ten eligible patients are currently using GLP‑1 therapies, citing barriers such as cost, stigma, and perceived complexity. Unlike Wegovy, which must be taken on an empty stomach each morning, Foundayo can be taken anytime of day regardless of meals, simplifying dosing schedules. Patients will start on a low dose that is gradually increased to mitigate side‑effects. Pricing is projected at $149 per month for the initial dose, with higher‑strength formulations potentially reaching $349 monthly. While private‑insurance coverage remains uncertain, a Trump‑administration proposal could allow Medicare to cover certain patients as early as this summer, with copayments as low as $50 per month. Distribution will commence on Monday through LillyDirect’s direct‑to‑consumer channel, with broader availability in pharmacies and telehealth platforms expected shortly thereafter. The convenience of a once‑daily pill is anticipated to improve adherence, especially for individuals who avoid injectables due to needle aversion or rigid dosing requirements. The approval follows a fast‑track submission submitted only months ago, positioning Foundayo to enter the market roughly three months after Wegovy. This rapid rollout is set to intensify competition in the burgeoning GLP‑1 space, where new agents are continually emerging with claims of better efficacy and lower costs.

Tiger Woods announced he is pausing his golf career to focus on health and treatment after a police stop near his Jupiter Island, Florida home that led to a DUI suspicion charge.In a statement posted on X, Woods said, "I know and understand the seriousness of the situation I find myself in today. I am stepping away for a period of time to seek treatment and focus on my health. This is necessary in order for me to prioritize my well‑being and work toward lasting recovery." He added that he hopes to return "healthier, stronger, and more focused" and asked for privacy for his family.According to court records released Tuesday, Woods entered a plea of not guilty and has asked for a jury trial. The incident occurred on a residential road when his Land Rover clipped a truck, crossed a double yellow line, and rolled onto its driver’s side, causing roughly $5,000 in property damage to the other vehicle.Deputies observed several signs of impairment, including profuse sweating, bloodshot and glassy eyes, and lethargic speech and movements. Woods told investigators he had not consumed alcohol but had taken "a few" prescription medications, including Vicodin, blood‑pressure medication, and cholesterol medication. A search of his pocket uncovered two hydrocodone pills, a prescription opioid.While Woods refused a urine test for drugs, a breathalyzer showed no alcohol in his system. He was charged with misdemeanor DUI, property damage, and refusal to submit to testing. After a brief hospital clearance, he was held for the mandatory eight‑hour Florida detention period before posting $1,150 bail.Former President Donald Trump commented on the situation, noting Woods’ extensive injury history and stating, "He tested negative for alcohol... He lives a life of pain. He doesn’t have an alcohol problem, but he does have pain." Trump also mentioned Woods’ relationship with his former daughter‑in‑law, Vanessa Trump.Woods’ attorney, Douglas Duncan, filed a waiver of arraignment and a demand for a jury trial, moving his initial court appearance to a docket‑sounding hearing scheduled for May 5. The golfer has not competed in a PGA Tour event since July 2024, though he appeared in the TGL indoor league last week.Prior to the crash, Woods was listed for the US Senior Open and was undecided about playing in the upcoming Masters at Augusta National, leaving his future tournament schedule uncertain.

Israeli and U.S. forces launched a series of air strikes on Tuesday that struck Tofigh Daru Research and Engineering Company, one of Tehran’s largest producers of anaesthetics and anti‑cancer medicines. The state‑run firm, owned by the Social Security Investment Company, saw its drug‑production line damaged, according to an official post on X. In the north‑western city of Zanjan, a separate strike hit the Husseiniya Azam, a Shia congregation hall adjacent to a mosque. Iranian Red Crescent teams rescued two people from the rubble; one of the victims died and several others were injured. Further attacks were reported in the western province of Kermanshah, where a civilian contracting company in Qasr‑e Shirin – a border town with Iraq – was hit. One person was killed and eight injured, the Mehr news agency said. Heavy bombing was also confirmed in Isfahan, a strategic hub for Iran’s defence industry and home to key nuclear facilities such as Natanz. Local officials indicated that the strikes may have targeted “military sites,” though the exact locations and damage assessments remain unclear. Iranian officials condemned the operations. Former foreign minister Javad Zarif denounced the targeting of the pharmaceutical plant as a deliberate attack on a medical facility, calling the aggressors “desperate” and accusing them of “diabolical delusions.” Governor‑level security official Akbar Salehi echoed these concerns, noting that the strikes appeared aimed at military installations without specifying which ones. The broader conflict has already claimed 1,937 Iranian lives since the joint U.S.–Israeli campaign began on 28 February, while 20 Israelis have been killed. Recent Israeli interceptions using the Iron Dome and David’s Sling systems have limited damage on Israeli soil, but impact sites were reported in Tel Aviv, Bnei Brak and Petah Tikva. Amid the escalating violence, diplomatic channels remain active. U.S. Secretary of State Marco Rubio told Al Jazeera that communications between Washington and Tehran continue, primarily through intermediaries, and that the U.S. aims to achieve its war objectives “in weeks, not months.” Pentagon chief Pete Hegseth added that negotiations to end the conflict are “very real, ongoing and gaining strength.” Iran’s Islamic Revolutionary Guard Corps (IRGC) claimed a retaliatory strike, saying it hit an Israeli container ship in the Gulf with a ballistic missile and that Iranian drones targeted a group of U.S. Marines near a UAE military base. Public sentiment in Iran has turned sharply hostile, with pro‑state demonstrations erupting in Tehran as citizens protest the continued air raids. The atmosphere, described by Al Jazeera’s Tohid Asadi as a “cloud of mistrust,” reflects growing frustration over diplomatic dead‑ends and the relentless cycle of attacks.

Amnesty International has warned that the 2026 FIFA World Cup will be staged during an "acute human‑rights crisis" that endangers travelling supporters, local residents and tournament staff across the three host nations.The rights group released its report on Monday, highlighting the dangers facing millions of fans who will journey to the United States, Canada and Mexico for the six‑week event.The United States, which will host three‑quarters of the matches (78 of 104 fixtures), is described as undergoing a "human‑rights emergency" marked by a pattern of authoritarian practices. Amnesty points to recent immigration crackdowns, restrictive protest laws and a series of deaths at the hands of U.S. law‑enforcement officials.According to the report, at least six detainees died in ICE custody in 2026, with a seventh person fatally shot by an off‑duty ICE officer. The agency recorded 32 deaths in ICE custody the previous year, many attributed to health complications but accompanied by allegations of abuse and medical neglect.Although FIFA classified the tournament as a "medium‑risk" event, Amnesty warns it could become "a stage for repression and a platform for authoritarian practices" if host governments fail to safeguard basic freedoms.Key concerns raised include:Forced shutdowns of protests, gender bias, indiscriminate raids, ethnic profiling and mass detentions.U.S. visa bans targeting nationals from 12 countries—four of which have qualified for the World Cup—deemed racial discrimination under international law.Mexico’s internal security challenges following a wave of violence triggered by the killing of a major drug‑lord, and planned peaceful demonstrations by women’s groups seeking justice for the country’s 133,500 disappeared persons.Canada’s looming housing crisis that could displace homeless individuals, alongside reported violence and harassment directed at the LGBTQ community.Amnesty also criticised President Donald Trump, who received FIFA’s newly created Peace Prize in December 2025, and FIFA President Gianni Infantino for praising the award. The report accuses the Trump administration of dismantling international cooperation mechanisms, engaging in aggression in Venezuela, conducting extrajudicial air strikes in Latin America and collaborating with Israel on attacks against Iran.Despite the criticism, FIFA projects to generate $11 billion in revenue from the World Cup cycle. Amnesty’s head of economic and social justice, Steve Cockburn, stressed that “fans, communities, players, journalists and workers cannot be made to pay the price” and that their rights must be central to the tournament’s planning.The tournament is set to kick off on June 11 at Mexico City’s stadium, with the final slated for July 19 at New Jersey’s MetLife Stadium.

Jurors in two separate U.S. courts delivered historic rulings that, for the first time, hold major social‑media platforms financially accountable for designs that allegedly harm young users. In New Mexico, a jury ordered Meta to pay $375 million for claims that its products contributed to child sexual exploitation and other harms. The following day, a California jury found both Meta and YouTube liable, imposing $6 million in damages for deliberately engineering addictive experiences. The verdicts arrive amid a wave of lawsuits filed by more than 2,000 plaintiffs—including families, school districts, and state attorneys general—targeting Meta, YouTube, TikTok and Snap. While both companies have announced intentions to appeal, the judgments signal a shift from public criticism to concrete legal exposure. During the trials, Meta’s defense repeatedly cited the American Psychiatric Association’s position that “social media addiction is not a thing” in the DSM‑5‑TR. The APA countered that the absence of a formal diagnosis does not negate the phenomenon’s existence, emphasizing growing research on the mental‑health impacts of compulsive platform use. Internal communications presented as evidence painted a starkly different picture. A 2020 Meta email exchange described Instagram as “a drug” and likened the company’s role to that of “pushers,” while another message warned that targeting 11‑year‑olds resembled tactics once used by tobacco firms. Similar concerns emerged from YouTube, where an internal document explicitly stated the goal was “not viewership, it’s viewer addiction.” TikTok’s own research echoed these findings, concluding that users could become addicted in under 35 minutes and that compulsive usage correlates with a range of negative mental‑health outcomes. Moody’s, a risk‑assessment firm, warned that the dual verdicts establish a precedent whereby design‑driven user harm can trigger liability. In an analysis, analysts Adam Grossman and Taro Ramberg noted that insurers should focus on the emerging “design‑centered liability theory,” which links engagement‑driven features—such as infinite scrolling and autoplay—to compensable injuries. They cautioned that the current cases are merely the first data points in a broader legal trend. Beyond social media, the same design principles appear in video games, sports‑betting platforms, AI chatbots and online retail. Moody’s tracker lists over 1,100 pending cases in Los Angeles alone and estimates roughly 4,000 lawsuits targeting 166 U.S. companies for allegedly addictive software design. Both Meta and YouTube maintain that they disagree with the verdicts. YouTube’s spokesperson called the California decision a “misunderstanding” of the platform’s nature, while Meta emphasized the complexity of teen mental health and the non‑unanimous nature of the California jury’s finding. Nevertheless, the courts have signaled that even without a settled clinical definition of “social‑media addiction,” companies can be held responsible for the foreseeable harms of their product designs.

Kenyan marathon runner Albert Korir, the 2021 New York City Marathon champion, has been handed a five-year doping ban by the Athletics Integrity Unit (AIU). Korir admitted to using a banned performance-enhancing drug, specifically the synthetic form of erythropoietin (EPO), which stimulates red blood cell production.The ban, which runs from January 8 until January 7, 2031, was reduced from six years due to Korir's early admission and acceptance of the sanction. The 32-year-old athlete tested positive during out-of-competition tests in Kenya in October.Korir has had a notable career, winning the 2021 New York marathon in a time of 2 hours, 8 minutes, and 22 seconds. He also came third in the 2023 New York marathon with a personal best time of 2:06:57. Additionally, he won the Ottawa Marathon in 2019 and 2025.This sanction comes as part of Kenya's ongoing efforts to clean up its image in athletics, following a string of doping scandals. Over 140 Kenyan runners, mainly long-distance athletes, have been sanctioned for drugs offences since the 2016 Rio de Janeiro Olympics. Recently, Kenya handed out its first lifetime ban to marathon runner Beatrice Toroitich and a six-year ban to 10km record holder Rhonex Kipruto in June 2024.

Eli Lilly, the US pharmaceutical group behind the Mounjaro weight-loss drug, is seeking to resume its investments in the UK after pausing them last year. The company is in talks with UK ministers to regularly increase NHS drug prices and end a rebate scheme. Patrik Jonsson, president of Eli Lilly's international business, expressed optimism about reaching an agreement this summer.The talks will also explore 'innovative' pricing plans, such as linking payments for anti-obesity drugs to whether the treatment helps patients return to work. This comes as the US pharmaceutical industry increases pressure on the UK, with Keir Starmer agreeing to the first increase in NHS cost-effectiveness thresholds in 27 years. The threshold was raised from £20,000 to £30,000 a year for every year of life gained to £25,000 to £35,000.Eli Lilly was one of several pharmaceutical companies that ditched or paused almost £25bn in planned investments in the UK last year. The company paused its plans to invest in a laboratory site in central London. Jonsson stated that the resumption of Eli Lilly's investment would depend on the outcome of its talks with the government.He emphasized that prices for medicines in the UK had been 'far too low for far too long' and that the threshold couldn't remain static for another three decades. The UK agreed to pay 25% more for new medicines by 2035 as part of a US-UK drug pricing deal, which could eventually reach £9bn a year.Large pharmaceutical companies have protested about a 'rebate' scheme, under which they are required to pay back a chunk of revenue from sales of branded medicines. This scheme is expected to fall in 2026, although Jonsson believes payments 'should actually get down to zero' over time.

Robert F Kennedy Jr, the US health secretary, has unveiled a chaotic and unpredictable agenda for public health policy under his 'Make America Healthy Again' (Maha) initiative. His approach tends to favor personal choice and autonomy over large-scale, mandatory public health interventions, such as childhood vaccine requirements.The Maha agenda has raised concerns over the potential risks associated with injectable peptide drugs. Mr. Kennedy plans to open up the sale of 'about 14' of these drugs to the public, despite the US Food and Drug Administration (FDA) restricting 17 peptides in 2023 due to 'potential significant safety risks'. None of these peptides have been proven to be safe or effective for human use.The peptides in question are often promoted for biological enhancement, such as increasing muscle mass or cognitive benefits, but the evidence for these effects in humans is thin. Reports of people self-administering peptide therapies, usually bought from China 'for research use only', are widespread, particularly in Silicon Valley.The Maha project wants to make the grey market the only market, effectively sanctioning mass public use of unproven treatments. Peptides are clearly drugs and shouldn’t be allowed for widespread use without rigorous clinical trials. Opening loopholes for sale would undermine the precautionary principle that has successfully led public health policy for generations.It is also worth noting that other governments are unlikely to be as cavalier as Mr. Kennedy about peptides. However, people everywhere will continue to call for more personal choice and more bodily autonomy, and those conversations are important. The case for safety, proof, and regulation must be made to ensure that public health policy prioritizes the well-being of individuals.